EDINBURGH, Scotland, December 30, 2024 — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies, announced that its shareholders approved the previously announced 25% stock dividend.
The Company declared that the 25% stock dividend, approved at its General Meeting, consists of 0.25 American Depositary Shares (“ADSs”) per 1 ADS held as of January 2, 2025. Shareholders should receive these dividends around January 6th.
TC BioPharm CEO, Bryan Kobel, commented: “This special dividend is a key part of our capital management strategy, demonstrating our confidence in the Company’s future. We expect 2025 to bring growth and enhanced shareholder value.”
To accommodate the stock dividend, Nasdaq will halt trading of the Company’s ADSs at 5:00 pm on January 2, 2025, resuming around January 8, 2025. The opening price on January 8 will be adjusted to reflect the dividend’s dilution effect.
This release is for informational purposes only and does not constitute an offer to sell or buy any securities. For more details on the General Meeting, please see our website and filings (Form 6K).
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on developing gamma-delta T-cell therapies for cancer, leveraging human efficacy data in acute myeloid leukemia. Gamma-delta T cells possess properties of both innate and adaptive immune systems, distinguishing between healthy and diseased tissue.
TC BioPharm leads gamma-delta T cell therapy development, having conducted phase II/pivotal clinical studies in oncology. The Company is running two investigator-initiated trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for acute myeloid leukemia using its allogeneic CryoTC technology for global clinic distribution.
Forward-Looking Statements for TC BioPharm
This press release includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. Statements not related to historical facts are forward-looking, including those concerning budget savings, M&A, and capital raising. These statements reflect current assumptions and involve risks and uncertainties. For details on potential differences between actual and projected results, see the “Risk Factors” section of our Form 10-K for the year ended December 31, 2023, and other SEC filings available on our Investor Relations website and the SEC website at . Forward-looking statements reflect our beliefs only as of the date of this release. We have no obligation to update them.
SOURCE TC BioPharm
“`